LUMICKS
Company

Last deal

$70M
Local Amount - EUR 77.6M

Amount

Series D

Stage

16.04.2021

Date

5

all rounds

$70.3M

Total amount

General

About Company
LUMICKS provides instruments for analyzing single molecules and cells.

Industry

Sector :

Subsector :

Keywords :

founded date

01.03.2014

Number of employees

Company Type

For Profit

Last funding type

Series D

IPO status

Private

Description

LUMICKS offers cutting-edge technologies, such as optical tweezers and super-resolution microscopy, that allow researchers to study the behavior and interactions of single molecules and cells in real-time. Their tools enable the measurement of forces and interactions in biology, bridging the gap between structural and functional analysis at the molecular and cellular levels. With their C-Trap Optical Tweezers and Fluorescence Microscopy, scientists can analyze complex biological processes, while the z-Movi Cell Avidity Analyzer allows the measurement and selection of immune cells based on their interactions with target cells. LUMICKS aims to advance scientific understanding and improve human health by unlocking the analysis of single molecules and cells, contributing to the prevention and development of future cures for diseases like cancer.
Contacts